Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Joins Canadian Personalized Oncology Consortium

NEW YORK (GenomeWeb) – Canadian molecular diagnostics firm Contextual Genomics and the Personalized Medicine Initiative today announced that AstraZeneca has joined their National Access Project consortium.

AstraZeneca has provided a grant for an undisclosed amount and will provide technical advice as part of its commitment to the project.

The National Access Project for Cancer Testing, managed by the Personalized Medicine Initiative with testing provided by Contextual Genomics, launches this month. The consortium's goal is to make genomic testing available to any Canadian diagnosed with cancer to improve precision in diagnosis, enable tailored treatment options, and support better health outcomes.

The program will provide a free 90-mutation genomic tumor profiling test for 2,000 cancer patients at ten centers across Canada.

Additional companies are expected to join the National Access Project consortium, the organizations said in a statement.